Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

StatusUnknown
PhasePhase 1/2
Started

Record status This record was last updated June 27, 2023 (before its estimated April 10, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2023); last known: Active, Not Recruiting
  2. Secondary endpoints: details revised at 1 of 7 entriesv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fudan University
634 trials monitored
See 8 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer
Trial Details
NCT Number NCT05824325
Lead Sponsor Fudan University
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov